Canntab Therapeutics Limited (CTABF)

USD 0.0

(0.0%)

Market Cap (In USD)

147.01 Thousand

Revenue (In USD)

293.36 Thousand

Net Income (In USD)

-3.68 Million

Avg. Volume

172.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-0.0091
PE
-
EPS
-
Beta Value
1.868
ISIN
CA1377991023
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Richard C. Goldstein
Employee Count
-
Website
https://canntab.ca
Ipo Date
2017-11-28
Details
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.